http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
치료 불응성 Still's병에서 자가 조혈모세포 채집시 사용된 G-CSF에 의한 급성 악화 1예
이재웅,박성현,왕준광,오호석,최정혜,배상철,이영열,김인순,최일영,안명주 대한조혈모세포이식학회 2003 대한조혈모세포이식학회지 Vol.8 No.2
치료 불응성 자가면역질환에서 고용량 항암화학요법 및 자가 조혈모세포이식술이 시행되고 있으나 조혈모세포 가동화 및 이식술 시 사용되는 G-CSF에 의해 오히려 기존의 자가면역질환의 증세가 악화되었다는 보고가 있다. 저자들은 만성적으로 재발되는 Still's병 환자에서 조혈모세포 가동화를 위해 사용한 G-CSF에 의해 자가면역질환이 급성 악화된 1예를 경험하였기에 보고하는 바이다. High-dose immunosuppressive therapy with autologous stem cell transplantation is an increasingly used treatment for severe refractory autoimmune disorder including multiple sclerosis, rheumatoid arthritis, juvenile chronic arthritis, systemic lupus erythematosus. Although the optimal method of collecting stem cell is not determined, G-CSF-based mobilization is generally considered safe. However, worsening of disease status was reported in autoimmune disease undergoing mobilization with G-CSF. We report a 24-year-old male with refractory Still's disease who developed acute disease flare after administration of G-CSF for stem cell mobilization.
서울의 Penicillinase Producing Neisseria Gonorrhoeae 발생빈도(1996)
김재홍,황동규,전재홍,김윤석,김중환,김용준,이창균,임동진,김현수,조창근,김경문,박상훈,전우형,김희성,이호정,차명수,김갑형,김형석,김석우,황지환,박병순,권오상,이민수,송기훈,성소영,이인섭,부태성 대한화학요법학회 1999 대한화학요법학회지 Vol.17 No.2
Background : In recent years, gonorrhea has been panedemic and remains one of the most commom STDs in the world, especially in developing countries. Objective & Methods: For the detection of a more effective therapeutic regimen and assessing the prevalence of PPNG, we have been trying to study the patients who have visited the VD Clinic of Choong-Ku Public Health Center in Seoul since 1980 by means of the chromogenic cephalosporin method. Results: In 1996, 139 strains of N. gonorrhoeae were isolated, among which 53(39.0%) were PPNG. Conclusion: Our results suggests that after a peak of 74.3% in 1993, the prevalence of PPNG in Seoul is gradually declining.
Myung-Ju Ahn,Ho-Suck Oh,최정혜,Young-Yeul Lee,In-Soon Kim,Il-Young Choi,Oh Young Lee,Ho-Soon Choi,Sung-Joon Kwon 대한암학회 2004 Cancer Research and Treatment Vol.36 No.3
PURPOSE: To evaluate the efficacy and toxicity of heptaplatin, paclitaxel, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer. MATERIALS AND METHODS: Between July 2002 and September 2003, nineteen patients were enrolled in this study. Paclitaxel 135 mg/m2 iv on day 1, heptaplatin 400 mg/m2 iv on day 2 and 5-fluorouracil 800 mg/m2 on day 2~4 were administered and the regimen was repeated every 3 weeks. RESULTS: The median age of the patients was 60 years (range: 32~74) and the most common sites of metastasis were liver and lymph nodes. In the 16 evaluated patients, the overall response rate was 43.8%, but this was without any complete response. The median time to disease progression was 3.93 months (range: 0.26~8.1) and the median response duration for the 7 responding patients was 3.83 months (range: 1.48~6.07). The median overall survival for 19 patients was 7.01 months (range: 0.26~17.44). A median of 3 cycles (range: 1~7) and a total of 65 cycles were administered and evaluated for toxicity. The most common hematologic toxicities were NCI grade I/II anemia (47.7%), neutropenia (9.2%) and thrombocytopenia (6.2%). The most common non-hematologic toxicities more than grade II were nausea/vomiting (30.8%/9.2%). One elderly patient with ECOG 2 had a life- threatening complication of pneumonia. CONCLUSION: The combination of heptaplatin, paclitaxel, and 5-fluorouracil showed significant activity and favorable toxicity profiles in patients with advanced gastric cancer. However, one elderly patient who had poor performance experienced a life-threatening toxicity/complication. Our results suggest that the efficacy of this combination chemotherapy can be maximized when administered to the patients with good performance status. Further studies with large numbers of patients and long-term follow-up study will be needed. (Cancer Res Treat. 2004;36:182-186)
( Myung Gyu Choi ),( Poong Lyul Rhee ),( Hyojin Park ),( Oh Young Lee ),( Kwang Jae Lee ),( Suck Chei Choi ),( Sang Young Seol ),( Hoon Jai Chun ),( Jong Sun Rew ),( Dong Ho Lee ),( Geun Am Song ),( H 대한소화기기능성질환·운동학회 2015 Journal of Neurogastroenterology and Motility (JNM Vol.21 No.3
Background/Aims: Therapies of functional dyspepsia (FD) are limited. DA-9701 is a novel prokinetic agent formulated with Pharbitis semen and Corydalis Tuber. We aimed to assess the efficacy of DA-9701 compared with itopride in FD patients. Methods: Patients with FD randomly received either itopride 50 mg or DA-9701 30 mg t.i.d after a 2-week baseline period. After 4 weeks of treatment, 2 primary efficacy endpoints were analyzed: the change from baseline in composite score of the 8 dyspeptic symptoms and the overall treatment effect. Impact on patients`` quality of life was assessed using the Nepean Dyspepsia Index (NDI) questionnaire. Results: We randomly assigned 464 patients with 455 having outcome data. The difference of the composite score change of the 8 symptoms between the 2 groups was 0.62, indicating that DA-9701 was not inferior to itopride. The overall treatment effect response rate was not different between the groups. When responder was defined as ≥ 5 of the 7 Likert scale, responder rates were 37% of DA-9701 and 36% of itopride group. Patients receiving DA-9701 experienced similar mean percentage of days with adequate relief during the 4-week treatment period compared with those receiving itopride (56.8% vs 59.1%). Both drugs increased the NDI score of 5 domains without any difference in change of the NDI score between the groups. The safety profile of both drugs was comparable. Conclusions: DA-9701 significantly improves symptoms in patients with FD. DA-9701 showed non-inferior efficacy to itopride with com - parable safety. (J Neurogastroenterol Motil 2015;21:414-422)
Myung Ju Ahn,Young Do Yoo,Ki Hwan Lee,Joon Ik Ahn,Dong Hyun Yu,Hye Sook Lee,Ho Suck Oh,최정혜,Yong Sung Lee 대한암학회 2005 Cancer Research and Treatment Vol.37 No.1
Purpose: Gastric cancer is one of the most prevalent cancers worldwide. 5-fluorouracil (5-FU) and cisplatin are the most commonly used drugs for the treatment of gastric cancer. However, a significant number of tumors often fail to respond to chemotherapy. Materials and Methods: To better understand the molecular mechanisms underlying drug resistance in gastric cancer the gene expression in gastric cancer cells, which were either sensitive or resistant to 5-FU and cisplatin, were examined using cDNA microarray analysis. To confirm the differential gene expression, as determined using the microarray, semiquantitative RT-PCR was performed on a subset of differentially expressed cDNAs. Results: 69 and 45 genes, which were either up-regulated (9 and 22 genes) or down-regulated (60 and 25 genes), were identified in 5-FU- and cisplatin-resistant cells, respectively. Several genes, such as adaptor-related protein complex 1 and baculoviral IAP repeat-containing 3, were up-regulated in both drug-resistant cell types. Several genes, such as the ras homolog gene family, tropomyosin, tumor rejection antigen, protein disulfide isomerase-related protein, melanocortin 1 receptor, defensin, cyclophilin B, dual specificity phosphatase 8 and hepatocyte nuclear factor 3, were down-regulated in both drug- resistant cell types. Conclusion: These findings show that cDNA microarray analysis can be used to obtain gene expression profiles that reflect the effect of anticancer drugs on gastric cancer cells. Such data may lead to the assigning of signature expression profiles of drug-resistant tumors, which may help predict responses to drugs and assist in the design of tailored therapeutic regimens to overcome drug resistance.